

**Claims:**

1. An aqueous formulation comprising (-)-(R)-3-(2-hydroxymethylindanyl-4-oxy)phenyl 4,4,4-trifluorobutane-1-sulfonate (I) and cyclodextrin.  
5
2. A formulation as claimed in claim 1, comprising from 0.00005 to 9.0 g/l of the compound (I) and from 0.1 to 550 g/l of cyclodextrin.
3. A formulation as claimed in either of the preceding claims, comprising from  
10 0.0001 to 0.050 g/l of the compound (I) and from 0.2 to 200 g/l cyclodextrin.
4. A formulation as claimed in any of the preceding claims, comprising from 0.0005 to 0.025 g/l of the compound (I) and from 1 to 50 g/l cyclodextrin.
- 15 5. A formulation as claimed in any of the preceding claims, which has a pH of from 2 to 6.
6. A formulation as claimed in any of the preceding claims, comprising at least one physiologically tolerated acid.  
20
7. A formulation as claimed in claim 6, which comprises citric acid as physiologically tolerated acid.
8. A formulation as claimed in any of the preceding claims, comprising from 8  
25 to 10 g/l sodium chloride based on the formulation ready for use.
9. A formulation as claimed in any of the preceding claims, comprising from 0.05 to 2 g/l ethanol based on the formulation ready for use.
- 30 10. An administration kit consisting of

- 5
- a) a container comprising the aqueous formulation as claimed in claims 1 to 9,
  - b) infusion apparatus, where at least the parts which come into contact with the product consist of polyethylene, polypropylene, polyester, polyamide, acrylonitrile-butadiene-styrene copolymers, polypropylene/styrene-ethylene-butylene-styrene or copolymers thereof.